(Q83225307)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243032%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

title

CD49d blockade by natalizumab therapy in patients with multiple sclerosis increases immature B-lymphocytes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243032%20AND%20SRC:MED&resulttype=core&format=json

Marcelo De Carvalho Bittencourt

20 January 2020

author

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243032%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

J-F Lesesve

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243032%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

M Debouverie

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243032%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

M-C Béné

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243032%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

17 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243032%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

20 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243032%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

46

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243032%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243032%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

1489-1491

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243032%20AND%20SRC:MED&resulttype=core&format=json

CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function.

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.328

7 January 2021

The effects of natalizumab on the innate and adaptive immune system in the central nervous system

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.328

7 January 2021

Immune surveillance in multiple sclerosis patients treated with natalizumab.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.328

7 January 2021

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.328

7 January 2021

Membrane microdomains and proteomics: lessons from tetraspanin microdomains and comparison with lipid rafts

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.328

7 January 2021

B cells, antibodies, and tertiary lymphoid tissue in MS brains

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.328

7 January 2021